Chemo Centryx
Biotechnology, 835 Industrial Rd Ste 600, San Carlos, California, 94070, United States, 51-200 Employees
Phone Number: 65********
Who is CHEMOCENTRYX
ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoC...
Read More
-
Headquarters: 835 Industrial Rd Ste 600, San Carlos, California, 94070, United States
-
Date Founded: 1997
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from CHEMOCENTRYX
ChemoCentryx Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ChemoCentryx
Answer: ChemoCentryx's headquarters are located at 835 Industrial Rd Ste 600, San Carlos, California, 94070, United States
Answer: ChemoCentryx's phone number is 65********
Answer: ChemoCentryx's official website is https://chemocentryx.com
Answer: ChemoCentryx's revenue is $10 Million to $25 Million
Answer: ChemoCentryx's SIC: 2834
Answer: ChemoCentryx's NAICS: 541715
Answer: ChemoCentryx has 51-200 employees
Answer: ChemoCentryx is in Biotechnology
Answer: ChemoCentryx contact info: Phone number: 65******** Website: https://chemocentryx.com
Answer: ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Our goal is to change treatment paradigms in orphan and rare diseasespecifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month